A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies

The vast majority of patients with plasma cell neoplasms die of progressive disease despite high response rates to novel agents. Malignant plasma cells are very radiosensitive, but the potential role of radioimmunotherapy (RIT) in the management of plasmacytomas and multiple myeloma (MM) has undergo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Green, Damian J., Orgun, Nural N., Jones, Jon C., Hylarides, Mark D., Pagel, John M., Hamlin, Donald K., Wilbur, D.S., Lin, Yukang, Fisher, Darrell R., Kenoyer, Aimee L., Frayo, Shani L., Gopal, Ajay K., Orozco, Johnnie J., Gooley, Theodore A., Wood, Brent L., Bensinger, William I., Press, Oliver W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3970848/
https://ncbi.nlm.nih.gov/pubmed/24371230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1589
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados